I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| hepatocyte | 5 studies | 35% ± 9% | |
| enterocyte | 3 studies | 20% ± 2% | |
| fibroblast | 3 studies | 19% ± 3% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| hepatocyte | 5 studies | 35% ± 9% | |
| enterocyte | 3 studies | 20% ± 2% | |
| fibroblast | 3 studies | 19% ± 3% |
Insufficient scRNA-seq data for expression of HAAO at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 8671.84 | 226 / 226 | 99% | 120.41 | 403 / 406 |
| kidney | 100% | 1683.65 | 89 / 89 | 90% | 42.20 | 813 / 901 |
| pancreas | 100% | 1025.85 | 328 / 328 | 81% | 8.81 | 145 / 178 |
| thymus | 99% | 435.13 | 648 / 653 | 80% | 9.93 | 484 / 605 |
| stomach | 98% | 411.81 | 352 / 359 | 75% | 15.87 | 215 / 286 |
| intestine | 96% | 573.50 | 929 / 966 | 75% | 16.33 | 397 / 527 |
| prostate | 100% | 803.38 | 244 / 245 | 65% | 7.42 | 328 / 502 |
| uterus | 100% | 859.13 | 170 / 170 | 59% | 8.24 | 270 / 459 |
| lung | 98% | 381.46 | 565 / 578 | 54% | 5.94 | 625 / 1155 |
| bladder | 100% | 1054.00 | 21 / 21 | 49% | 7.41 | 246 / 504 |
| breast | 99% | 473.07 | 456 / 459 | 43% | 5.55 | 485 / 1118 |
| esophagus | 97% | 374.41 | 1408 / 1445 | 43% | 6.70 | 79 / 183 |
| ovary | 100% | 893.04 | 180 / 180 | 18% | 1.56 | 78 / 430 |
| adrenal gland | 98% | 370.20 | 254 / 258 | 20% | 2.65 | 45 / 230 |
| spleen | 100% | 391.76 | 241 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 6.87 | 1 / 1 |
| blood vessel | 100% | 1514.07 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| skin | 69% | 220.30 | 1255 / 1809 | 30% | 3.83 | 141 / 472 |
| adipose | 99% | 462.48 | 1190 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 97% | 19.94 | 28 / 29 |
| heart | 79% | 250.36 | 679 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 77% | 404.67 | 714 / 929 | 0% | 0 | 0 / 0 |
| brain | 42% | 80.20 | 1110 / 2642 | 26% | 2.22 | 183 / 705 |
| tonsil | 0% | 0 | 0 / 0 | 67% | 7.66 | 30 / 45 |
| eye | 0% | 0 | 0 / 0 | 50% | 11.99 | 40 / 80 |
| muscle | 16% | 27.23 | 131 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0046874 | Biological process | quinolinate metabolic process |
| GO_0046686 | Biological process | response to cadmium ion |
| GO_0019805 | Biological process | quinolinate biosynthetic process |
| GO_0009435 | Biological process | NAD biosynthetic process |
| GO_0070050 | Biological process | neuron cellular homeostasis |
| GO_0006569 | Biological process | tryptophan catabolic process |
| GO_0010043 | Biological process | response to zinc ion |
| GO_0043420 | Biological process | anthranilate metabolic process |
| GO_0034354 | Biological process | 'de novo' NAD biosynthetic process from tryptophan |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0000334 | Molecular function | 3-hydroxyanthranilate 3,4-dioxygenase activity |
| GO_0008198 | Molecular function | ferrous iron binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0009055 | Molecular function | electron transfer activity |
| Gene name | HAAO |
| Protein name | 3-hydroxyanthranilate 3,4-dioxygenase 3-hydroxyanthranilate 3,4-dioxygenase (EC 1.13.11.6) (3-hydroxyanthranilate oxygenase) (3-HAO) (h3HAO) (3-hydroxyanthranilic acid dioxygenase) (HAD) |
| Synonyms | |
| Description | FUNCTION: Catalyzes the oxidative ring opening of 3-hydroxyanthranilate to 2-amino-3-carboxymuconate semialdehyde, which spontaneously cyclizes to quinolinate. . FUNCTION: Catalyzes the oxidative ring opening of 3-hydroxyanthranilate to 2-amino-3-carboxymuconate semialdehyde, which spontaneously cyclizes to quinolinate. . |
| Accessions | P46952 C9IY88 ENST00000431905.1 ENST00000294973.11 [P46952-1] |
